Real-world assessment of ipi-nivo in anti-PD-(L)-1 refractory Merkel Cell Carcinoma

2022
Real world evaluation of ipilimumab/nivolumab in PD-1/PDL-1 refractory MCC
Author

Sophia-Shalhout

Published

March 25, 2022

Details:

Event: Multicenter Merkel Cell Interest Group Meeting, Boston Massachusetts

This site represents our opinions only. See our full Disclaimer and Terms of Use Agreement